Consultation: Proposal to control zuranolone under the Controlled Drugs and Substances Act
Current status: Open
Opened on February 7, 2026, and will close to new input on April 18, 2026.
Health Canada has proposed that zuranolone, the active ingredient in the prescription drug ZURZUVAE™, be added to Schedule IV to the Controlled Drugs and Substances Act (CDSA), and that it be regulated as a targeted substance.
Zuranolone is available in Canada by prescription only. This would continue to be the case if zuranolone is scheduled under the CDSA. If zuranolone is controlled, it would be illegal to produce, package, sell, provide, import, or export this drug without appropriate authorizations (such as a licence) from Health Canada.
Controlling zuranolone under the CDSA would increase oversight and help minimize the chances of this drug being misused or diverted to the illegal market.
Join in: How to participate
We invite you to provide comments on this proposal during the 70 day public comment period.
Read our Notice of Intent for more details on the proposal.
Send us an email
Send an email to csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca with your ideas or comments to make yourself heard.
Who is the focus of this consultation
We are looking for comments from:
- Industry and industry associations
- Health care professionals
- Law enforcement
- Researchers
- Interested members of the public
Key questions for discussion
Your ideas and inputs are sought around:
- Whether you agree or disagree with this proposal and why
- Any potential impacts that the long-term control of zuranolone could have
Related information
Contact us
Office of Legislative and Regulatory Affairs
Controlled Substances and Overdose Response Directorate
Controlled Substances and Cannabis Branch
Health Canada
Email: csd.regulatory.policy-politique.reglementaire.dsc@hc-sc.gc.ca